Lumefantrine, with CAS number 82186-77-4, is a pharmaceutical substance used primarily in the treatment of malaria. It is a synthetic antimalarial agent that belongs to the artemisinin-based combination therapy (ACT) class of drugs. Lumefantrine is commonly combined with another antimalarial drug called artemether to form a highly effective treatment for uncomplicated malaria caused by Plasmodium falciparum.
Lumefantrine works by inhibiting the growth and replication of the malaria parasite within the red blood cells. It targets the parasite’s mitochondrial electron transport chain, leading to disruption of its energy metabolism and ultimately causing its death. The drug is administered orally in tablet form and is generally well-tolerated, with a favorable safety profile.
Due to the emergence of artemisinin resistance in some regions, lumefantrine has become an essential component in the fight against malaria. The combination therapy of lumefantrine and artemether has proven to be highly effective, providi
